VTV THERAPEUTICS INC.
Last · —$27.52-0.71 (-2.52%)live · yahoo · 0s ago
Vol 20.1K ≈ 553.2K
MA10MA20MA50
Market cap$108.81M4.0M sh
P/E · TTM—fwd — · eps —
Beta—vs S&P 500
Div yield0.00%annual · TTM
52w range
$20.23$42.72
Volume20.1Ksession
Issuer
Legal nameVTV THERAPEUTICS INC.
HQUnited States (US)
ListingUS VTVT
ISINUS9183852048
SectorHealthcare
IndustryBiotechnology & Medical Research
SIC2834
CurrencyUSD
Entity registrysec:0001641489
CIK0001641489
Websitewww.vtvtherapeutics.com
Employees26
AddressvTv Therapeutics, Inc. 3980 Premier Drive 27265, High Point +336 841 0300
| Revenue | $1.0M |
|---|---|
| Operating income | $-24.2M |
| Net income | $-18.5M |
| Free cash flow | $-25.3M |
| Operating margin | -2377.6% |
| Net margin | -1815.3% |
| Return on equity | -151.3% |
| Period | 2024 |
Loading chart…
OpenFilings analyst
Our analyst
10-K · 2026-03-10
From latest 10-K · 2026-03-10
- Operating Cf Burn
- Net Margin Sharply Negative
- Accumulated Deficit High
Red flags
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -1815.3%
- Accumulated Deficit High — Accumulated deficit / equity 507%
Upcoming earnings
FRI.13NOV
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
−$1.18
Est. revenue
0
Press & signals
- GlobeNewswire
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewswire
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewswire
vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags
Showing 5 of 63 filings